Literature DB >> 33857847

Cognitive training with fully immersive virtual reality in patients with neurological and psychiatric disorders: A systematic review of randomized controlled trials.

Frida Simon Jahn1, Marie Skovbye2, Kia Obenhausen3, Andreas Elleby Jespersen4, Kamilla Woznica Miskowiak5.   

Abstract

Cognitive impairment occurs across several neuropsychiatric diseases and impede everyday functioning and quality of life. Fully immersive Virtual Reality (VR) aid motivation and engagement and therefore has a potential to help overcome the obstacles in the field of cognitive rehabilitation. The aim of this systematic review is to investigate whether VR can be a useful intervention in cognitive rehabilitation transdiagnostically. We identified nine studies with randomized controlled trials following the PRISMA guidelines in databases Pubmed, Embase and PsychInfo. The trials were all evaluated through Cochrane Collaboration's Risk of Bias. The studies were conducted in patients with mild cognitive impairment (k=4), schizophrenia (k=3), ADHD (k=1), or stroke (k=1) and involved 6-12 weeks of training. Overall, results showed improvement in some domains of cognition, primarily executive function and attention. The studies were pilot studies with 6-34 participants per treatment group. Risk of bias was either high (k=3) or moderate (some concerns) (k=6). Key reasons were suboptimal statistical analyses and lack of clarification on randomization and blinding of participants and assessors. In conclusion, this review found promising evidence for VR cognitive rehabilitation for neuropsychiatric illnesses. However, larger and methodologically stronger studies are warranted to establish the full potential of VR.
Copyright © 2021. Published by Elsevier B.V.

Entities:  

Keywords:  Activities of daily living; Cognition; Cognitive dysfunction; Cognitive remediation; Mental disorders; Neurological rehabilitation; Social functioning

Year:  2021        PMID: 33857847     DOI: 10.1016/j.psychres.2021.113928

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  6 in total

1.  Commentary: Virtual Reality, Real Emotions: A Novel Analogue for the Assessment of Risk Factors of Post-traumatic Stress Disorder.

Authors:  Zhongyu Shi
Journal:  Front Psychol       Date:  2022-06-09

2.  Dynamic Visual Stimulations Produced in a Controlled Virtual Reality Environment Reveals Long-Lasting Postural Deficits in Children With Mild Traumatic Brain Injury.

Authors:  Thomas Romeas; Selma Greffou; Remy Allard; Robert Forget; Michelle McKerral; Jocelyn Faubert; Isabelle Gagnon
Journal:  Front Neurol       Date:  2021-11-25       Impact factor: 4.003

3.  A meta-analysis on neural changes of cognitive training for mental disorders in executive function tasks: increase or decrease brain activation?

Authors:  Jin Yang Li; Huiqin Wu; Shiting Yuan; Chun Wang; Qian Wang; Yuan Zhong; Ning Zhang; Kathi Heffner; Peter T Fox
Journal:  BMC Psychiatry       Date:  2022-03-01       Impact factor: 3.630

4.  Digital technology for addressing cognitive impairment in recent-onset psychosis: A perspective.

Authors:  Imogen Bell; Roos M C A Pot-Kolder; Stephen J Wood; Barnaby Nelson; Nicola Acevedo; Alexandra Stainton; Katie Nicol; James Kean; Shayden Bryce; Cali F Bartholomeusz; Amity Watson; Orli Schwartz; Rothanthi Daglas-Georgiou; Courtney C Walton; Donel Martin; Magenta Simmons; Isabel Zbukvic; Andrew Thompson; Jennifer Nicholas; Mario Alvarez-Jimenez; Kelly Allott
Journal:  Schizophr Res Cogn       Date:  2022-03-10

5.  Artificial Cognitive Systems Applied in Executive Function Stimulation and Rehabilitation Programs: A Systematic Review.

Authors:  Luis F Castillo-Ossa; Juan M Corchado; Carolina Robledo-Castro
Journal:  Arab J Sci Eng       Date:  2022-09-28       Impact factor: 2.807

Review 6.  Brain-Computer Interfaces Systems for Upper and Lower Limb Rehabilitation: A Systematic Review.

Authors:  Daniela Camargo-Vargas; Mauro Callejas-Cuervo; Stefano Mazzoleni
Journal:  Sensors (Basel)       Date:  2021-06-24       Impact factor: 3.576

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.